|

Oxaliplatin Clinical Trials

150 actively recruiting trials across 35 locations

▼ -1 trial since August 2026

Also known as: 1-OHP, 5FU + Oxaliplatin, Ai Heng, Aiheng, Dacotin +25 more

Pipeline

Phase 1: 25Phase 2: 65Phase 3: 30Phase 1/2: 19Phase 2/3: 6

Top Sponsors

  • Fudan University11
  • Astellas Pharma Global Development, Inc.7
  • Sun Yat-sen University5
  • Merck Sharp & Dohme LLC5
  • National Cancer Institute (NCI)4

Indications

  • Cancer150
  • Gastric Cancer17
  • Colorectal Cancer15
  • Gastroesophageal Junction Adenocarcinoma8
  • Locally Advanced Rectal Cancer7

Other86 trials

A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
Phase 1
A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer
Phase 3
A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer
Phase 2
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
Phase 2
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer
Phase 2
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors
Phase 1
A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer
Phase 1/2
A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer
Phase 2
A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)
Phase 3
A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure
Phase 3
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
Phase 1/2
A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer
Phase 1/2
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
Phase 1
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
Phase 1/2
A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
Phase 2/3
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase 3
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
Phase 1/2
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
Phase 3
ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer
Phase 1
Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety
Phase 2
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
Phase 2
Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)
Phase 2
CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer
Phase 2
CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer
Phase 2
Chemoradiation and Consolidation Chemotherapy With or Without Oxaliplatin for Distal Rectal Cancer and Watch and Wait
N/A
Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions
Phase 2
Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM
Phase 2
Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer
Phase 2
Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
Phase 2
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2
Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
Phase 2
Efficacy of Hyperthermic Intraperitoneal Chemotherapy
Phase 3
Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer
Phase 1/2
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
Phase 2
FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.
Phase 3
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Phase 2
Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer
Phase 2/3
Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.
Phase 3
HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)
Phase 3
Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer
Phase 2
IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
Phase 1/2
In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung
Phase 1
Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer
Phase 2
JS212 Combination Therapies in Metastatic Colorectal Cancer
Phase 2
Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV
Phase 1/2
Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)
Phase 2
Low Dose Epcoritamab Plus GemOx in R/R DLBCL
Phase 2
Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy
Phase 1/2
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
Phase 3
MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer
Phase 2
Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer
Phase 2
Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC
Phase 1/2
Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer
Phase 2
Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
Phase 2
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Phase 2/3
Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Phase 2
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
Phase 3
Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer
Phase 2
Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer
Phase 2
ONO-4538 Phase II Rollover Study (ONO-4538-98)
Phase 2
Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt-
N/A
Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)
Phase 3
PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
Phase 3
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Phase 2
Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer
Phase 2
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
Phase 1/2
Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.
N/A
SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases
Phase 2
SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC
N/A
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
Phase 2
Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer
Phase 2
Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer
Phase 2
Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)
Phase 2
Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Phase 2
Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma
Phase 3
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
Phase 3
Study to Evaluate the Use of Capecitabine in Monotherapy and in Combination With Oxaliplatin in Elderly Patients as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer.
Phase 2
The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer
Phase 2
The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer
Phase 2
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
Phase 2
The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma
Phase 2
The Role of Coenzyme Q10 in the Prophylaxis of Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer
Phase 1
The Sagittarius Trial
Phase 3
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
Phase 2/3
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
Phase 2
Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer
Phase 2/3

Duarte, California8 trials

A Study of ASP3082 in Adults With Advanced Solid Tumors

City of Hope National Medical Center

Phase 1
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

City of Hope National Medical Center /ID# 270255

Phase 2
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Phase 1
Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

City of Hope Medical Center

Phase 2
FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery

City of Hope Medical Center

Phase 2
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

City of Hope

Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

City of Hope Medical Center

Phase 1
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Phase 1/2

Birmingham, Alabama6 trials

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

O Neal Comprehensive Cancer Center at UAB

Phase 1/2
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

UAB Medicine - UAB Hospital

Phase 3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Research Site

Phase 3
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

University of Alabama at Birmingham Cancer Center

Phase 2
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

University of Alabama at Birmingham Cancer Center

Phase 3
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

University of Alabama at Birmingham Cancer Center

Phase 3

Phoenix, Arizona5 trials

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Mayo Clinic - Arizona ( Site 0090)

Phase 3
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Local Institution - 0005

Phase 2
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

Mayo Clinic Hospital

Phase 1
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

Mayo Clinic Arizona

Phase 2
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

Cancer Center at Saint Joseph's

Phase 3

Tucson, Arizona3 trials

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

University of Arizona Cancer Center - North Campus

Phase 3
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

The University of Arizona Cancer Center-North Campus

Phase 3
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927)

Phase 1/2

Los Angeles, California3 trials

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

START Los Angeles, LLC

Phase 1/2
AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

UCLA / Jonsson Comprehensive Cancer Center

Phase 1
Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

UCLA / Jonsson Comprehensive Cancer Center

Phase 1

Bethesda, Maryland3 trials

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

National Institutes of Health Clinical Center

Phase 1/2
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery

National Heart, Lung, and Blood Institute (NIH) (Data Collection Only)

Phase 2
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

National Institutes of Health Clinical Center

Phase 1

Anchorage, Alaska2 trials

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Research Site

Phase 3
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

Alaska Oncology & Hematology, LLC

Phase 2

Gilbert, Arizona2 trials

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Banner MD Anderson Cancer Center

Phase 3
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

Banner MD Anderson Cancer Center

Phase 3

Glendale, Arizona2 trials

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Palo Verde Hematology Oncology

Phase 3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Palo Verde Hematology/ Oncology Center, Ltd. ( Site 0175)

Phase 2/3

Tampa, Florida2 trials

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

Moffitt Cancer Center ( Site 0261)

Phase 1
Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors

Moffitt Cancer Center

Phase 2

Baltimore, Maryland2 trials

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Phase 2
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center

Phase 2

Boston, Massachusetts2 trials

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

Massachusetts General Hospital

Phase 1
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

Massachusetts General Hospital (Data Collection Only)

Phase 2

Houston, Texas2 trials

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

M D Anderson Cancer Center

Phase 1
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

MD Anderson Cancer Center

Phase 1

Huntsville, Alabama1 trial

Pan Tumor Rollover Study

Local Institution - 0220

Phase 2

Fairbanks, Alaska1 trial

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

Fairbanks Memorial Hospital

N/A

Goodyear, Arizona1 trial

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

I-Mab Site 1016

Phase 2

Anaheim, California1 trial

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Los Angeles Cancer Network

Phase 3

Cerritos, California1 trial

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

Helios Clinical Research

Phase 2

La Jolla, California1 trial

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

UC San Diego Moores Cancer Center

Phase 1

Orange, California1 trial

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

University of California Irvine Medical Center

Phase 1

Sacramento, California1 trial

Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

University of California Davis Comprehensive Cancer Center

Phase 2

Santa Monica, California1 trial

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

UCLA

Phase 2

New Haven, Connecticut1 trial

A Study of ASP1002 in Adults for Treatment of Solid Tumors

Yale University Cancer Center

Phase 1

Gainesville, Florida1 trial

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

UF Health Cancer Institute - Gainesville

Phase 1

Miami, Florida1 trial

SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer

University of Miami

Phase 1

Atlanta, Georgia1 trial

2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers

Emory University Hospital Midtown

Phase 2

Chicago, Illinois1 trial

Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

The University of Chicago

Phase 1

Mankato, Minnesota1 trial

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Mayo Clinic Health Systems-Mankato

Phase 2

Saint Louis Park, Minnesota1 trial

A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

Metro Minnesota Community Oncology Research Consortium

Phase 3

Basking Ridge, New Jersey1 trial

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Phase 1

Buffalo, New York1 trial

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Roswell Park Cancer Institute

Phase 1/2

Lake Success, New York1 trial

A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors

START New York

Phase 1/2

Chapel Hill, North Carolina1 trial

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center

Phase 2

Cleveland, Ohio1 trial

Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer

University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center

Phase 2

Pittsburgh, Pennsylvania1 trial

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

UPMC Hillman Cancer Center ( Site 1904)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.